Cartesian Therapeutics (NASDAQ: RNAC) granted employment inducement stock options to four new employees for an aggregate 115,250 common shares, with grant dates of August 3 and August 6, 2026. The exercise price for each option equals the Nasdaq Global Market closing price on the respective grant date.
According to Cartesian Therapeutics, the options vest over four years, with 25% vesting on the first anniversary of each grant date and the remaining 75% vesting in substantially equal monthly installments until August 2030. The options have a 10-year term, were issued under the Amended and Restated 2018 Employment Inducement Incentive Award Plan, and approved under Nasdaq Rule 5635(c)(4) as a material employment inducement.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Explained
Cartesian has granted options to purchase 115,250 common shares, not reported an immediate issuance of those shares; existing holders’ ownership can change only if the options are later exercised.
Market Context
Comparable inducement-grant news produced a 4.03% gain on July 2 and a -9.57% move on June 12, showi...
Analysis
Comparable inducement-grant news produced a 4.03% gain on July 2 and a -9.57% move on June 12, showing inconsistent precedent. Moderate short positioning added a sourced volatility consideration.
Key Figures
Employees receiving grants:4 employeesShares underlying options:115,250 sharesEffective grant dates:August 3, 2026 and August 6, 2026+5 more
Secured a credit facility providing up to $150 million in financing.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Comparable inducement-grant announcements produced mixed reactions, including a 4.03% gain on July 2 and a -9.57% move on June 12.
Key Terms
exercise price
1 terms
exercise pricefinancial
"The Options have an exercise price equal to the closing trading price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FREDERICK, Md., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to four new employees consisting of options to purchase an aggregate of 115,250 shares of the Company’s common stock with effective grant dates of August 3, 2026 and August 6, 2026. The Options have an exercise price equal to the closing trading price of the Company’s common stock on the Nasdaq Global Market on their respective grant dates, and will vest over a four-year period with 25% vesting on the first anniversary of their respective grant dates and the remaining 75% vesting in substantially equal monthly installments thereafter such that the options will be fully vested in August 2030. The options have a ten-year term. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees’ entry into employment with the Company.
About Cartesian Therapeutics
Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X.
What employment inducement grants did Cartesian Therapeutics (NASDAQ: RNAC) announce on August 7, 2026?
Cartesian Therapeutics granted stock options covering an aggregate 115,250 shares of common stock to four new employees. According to Cartesian Therapeutics, the options were approved as employment inducement awards with grant dates of August 3 and August 6, 2026 under its 2018 inducement plan.
What are the vesting terms of the new RNAC inducement stock options granted in August 2026?
The inducement options vest over four years, with 25% vesting on the first anniversary of each grant date. According to Cartesian Therapeutics, the remaining 75% vests in substantially equal monthly installments, leading to full vesting by August 2030, subject to continued employment.
How is the exercise price determined for Cartesian Therapeutics’ August 2026 inducement options?
The exercise price equals the closing trading price of RNAC common stock on the Nasdaq Global Market on each grant date. According to Cartesian Therapeutics, this market-based pricing applies separately to the August 3, 2026 and August 6, 2026 option grants.
What is the term of the new RNAC inducement stock options announced by Cartesian Therapeutics?
The newly granted inducement stock options have a 10-year term from their respective grant dates. According to Cartesian Therapeutics, this means each option can generally be exercised up to ten years after August 3, 2026 or August 6, 2026, subject to plan conditions.
Under which plan were Cartesian Therapeutics’ August 2026 inducement options granted?
The inducement options were granted under the Amended and Restated 2018 Employment Inducement Incentive Award Plan. According to Cartesian Therapeutics, the company’s board of directors approved these awards pursuant to this plan framework for newly hired employees.
How does Nasdaq Rule 5635(c)(4) apply to Cartesian Therapeutics’ new RNAC stock option grants?
The options were granted under Nasdaq Rule 5635(c)(4) as a material inducement to employment for the new hires. According to Cartesian Therapeutics, this rule permits equity awards to new employees outside shareholder-approved plans when used as an employment inducement.
How many new employees received the RNAC inducement option grants and what is the total share amount?
Four new employees received these inducement stock option awards, covering up to 115,250 shares of RNAC common stock in total. According to Cartesian Therapeutics, these equity grants were structured specifically to support the employees’ entry into employment with the company.
